JDCA letter detailing how the ADA can "win back" donor loyalty if they put more toward a cure.

Vertex’s phase I/II trial VX-880 is put under a protocol pause after two unrelated participant deaths. The next day, CRISPR Therapeutics announces Vertex (via ViaCyte) is ending collaboration early.

A comprehensive look at the year's progress toward a T1D Practical Cure. The 12th annual publication details Practical Cure pathways and the clinical trials pursuing them, an overview of donor priorities and the finances of the diabetes-focused nonprofits they donate to, a comprehensive section of stem cell research as a promising Practical Cure avenue, and more.